申请人:LG Life Sciences Ltd.
公开号:US06683095B2
公开(公告)日:2004-01-27
A novel 3-hydroxychromen-4-one derivative, pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase (“CDK”) is disclosed. Further, a process for preparing the compound and a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. is disclosed comprising the compound as an active component together with pharmaceutically acceptable carriers.
本发明揭示了一种新型的3-羟基香豆素衍生物,其药学上可接受的盐、水合物、溶剂合物或异构体,可用作细胞周期素依赖性激酶(“CDK”)的抑制剂。此外,本发明还揭示了一种制备该化合物的方法和一种组合物,该组合物作为活性成分与药学上可接受的载体一起用于抑制或治疗癌症和由细胞增殖引起的疾病,如炎症、血管狭窄、血管生成等。